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Abstract 
Aim: To investigate the prevalence of potential drug-drug interactions in primary healthcare 
clinics in the George subdistrict. Objectives included: To investigate and quantify the 
following risk factors: patient age, poly-pharmacy, gender, multiple prescribers and recorded 
diagnoses, as well as to identify and quantify the drugs involved, including the level of any 
drug-drug interactions. 
Design: A descriptive cross-sectional study was performed at four primary healthcare clinics 
in George from 400 randomly selected patients’ files for patients who attended these clinics 
from 1 February to 30 April 2010. Demographics, recorded diagnoses and all concurrently 
prescribed drugs were recorded and analysed. The level of drug-drug interaction was 
classified using the OpeRational Classification of drug-drug interactions designed by Hansten 
and Horn. 
Results: The prevalence for moderate interactions was 42%, severe interactions 5.25% and 
contraindicated combinations was 0.5%.  The most common drugs involved in potential drug 
interactions were: enalapril, aspirin, ibuprofen, furosemide and fluoxetine.  The most 
common drugs involved in potentially severe interactions were: warfarin, aspirin, fluoxetine, 
tramadol and allopurinol. Two contraindicated combinations were found: verapamil plus 
simvastatin, and hyoscine butyl bromide with oral potassium chloride. Increasing age and 
poly-pharmacy were associated with an increased risk for potential drug-drug interactions. 
Input from the regional hospital specialist departments greatly increased the risk of being 
prescribed a potential drug-drug interaction. Eighty one per cent (17/21) of severe 
interactions were from this group. The majority of patients in the sample were female 
(65.5%) but there was no differences in the percentage of drug interactions between males 
(43.4%) and females (43.1%). 
Conclusion: Potential drug-drug interactions are commonly prescribed in primary healthcare 
clinics in the George subdistrict. Drug interactions are predictable and preventable. It would 
seem prudent to put into place a method of reducing the risk. Further research is needed to 
identify effective interventions suitable for resource constrained centres. The risk factors 
identified in this study may assist in designing such an intervention. 
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Introduction 
In developed countries, drug-drug interactions (DDIs) are a recognised source of morbidity 
and mortality
1
. This has led to innovative means of addressing the issue including
computerised methods to detect potential interactions
2
. In developing countries like South
Africa, little work has been done to determine the extent of the problem and even less to 
reduce the risk. In a country where a significant percentage of the population is on anti-
retrovirals, anti-tuberculous drugs or medications for chronic diseases it would seem prudent 
to investigate and develop practical methods of reducing this risk.  
In the George subdistrict, primary healthcare practitioners saw and treated an average of 3450 
patients per day in four primary healthcare clinics during February to April 2010. Many of 
these patients have complex conditions and are managed by a number of doctors, including 
specialists from secondary and tertiary hospitals. The resultant discontinuity of multiple 
doctors and clinical nurse practitioners servicing these patients increases the potential for 
DDIs. In addition, large numbers of patients are elderly, suffer from chronic diseases and 
receive a multitude of medications.  
It would appear therefore that the likelihood of significant numbers of DDIs occurring in this 
context should be similar to that of other South African primary healthcare clinics and be at 
least as high as in countries where the problem has been researched
1-19, 21-41
. Adverse clinical
effects due to DDIs are often not recognised by health care practitioners and further 
medications are added to treat these signs and symptoms. Clinically, it may be difficult to 
decide between drug interactions, adverse reactions, side effects or deterioration of the 
patient’s condition as the cause of the presenting clinical picture3. Consider Mr H who
presents at an emergency centre with generalised muscle pains after a day’s gardening. The 
medical officer examines him and, finding nothing of significance prescribes diclofenac and 
sends him home. He presents two days later in severe pain with apparent haematuria and 
renal failure and is admitted. During admission it is discovered that the haematuria is in fact 
myoglobinuria secondary to rhabdomyolysis. Mr H has hypertensive heart disease and is on a 
number of drugs including simvastatin, prescribed by his physician. He developed tinea 
unguium of the toenails for which he was prescribed itraconazole by his general practitioner 
(GP) resulting in toxic levels of simvastatin and rhabdomyolysis. The potentially nephrotoxic 
diclofenac increased the likelihood of Mr H developing renal failure. 
Stellenbosch University  https://scholar.sun.ac.za
P
ag
e5
 
This and similar cases led to the question, “What is the prevalence of potential drug-drug 
interactions as reflected in the prescriptions of patients from primary healthcare clinics in the 
George subdistrict, which drugs are involved and what are the associated risk factors? 
Literature Review 
A Medline search using the terms “prevalence AND drug-drug interactions AND primary 
healthcare” returned 121 articles of which 37 were relevant. Other databases were searched 
but were not contributory. Many studies were found dealing with adverse drug reactions 
(ADRs) in elderly and hospitalised patients
1,4
 but few studies addressed ADRs in primary
healthcare (PHC).
2
 DDIs are a subset of ADRs that are preventable, but hardly any studies
dealt with DDIs in PHC and only two of these studies came from developing countries, viz. 
Mexico and South Africa.
7,20
The drugs involved varied from country to country and even from region to region, making it 
impossible to extrapolate data from other studies to the South African context. However 
warfarin was commonly implicated in severe interactions.
9, 12, 15, 19
. A systematic review of
the world-wide literature found that the top four drug classes comprised 51% of 
interactions
18
.
 Antiplatelets (16%)
 Diuretics (16%)
 NSAIDs* (11%)
 Anticoagulants (8%)
Risk factors for DDIs from the literature were: 
 Polypharmacy1, 4
 Extremes of age (very young5 or elderly9)
 Multiple co-morbidities1,4 especially cardiovascular disease7
 Greater number of prescribing physicians21
The prevalence of DDIs in the international literature ranges from 0.7% to 80%. Adverse 
drug reactions are the 6
th
 leading cause of in-hospital mortality in the United States
4
. In the
United Kingdom 3% of children on anti-epileptic medication were prescribed additional 
medications having potentially severe DDIs.
5
 Between 1964 and 2000 sixty-five childhood
deaths resulted from drug-interactions with anti-epileptic drugs
5
. In 2007 in Denmark, with
its highly computerised healthcare system, 94.3% of prescriptions had one or more 
*
 Non-steroidal anti-inflammatory drugs 
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inappropriate ratings in terms of the Medication Appropriate Index
6
. Only 0.7% of these were
due to drug-drug-interactions
6
. In an earlier (2003) study in Denmark, Bjerrum found that 4%
of hospital admissions were due to drug interactions
8
. While in 1993 Linnarson
3
 found a 12%
prevalence of Potential-DDIs (P-DDIs) in primary healthcare in Denmark. (The decrease in 
prevalence over time is possibly due to the increased use of computer-assisted decision 
making.) 
In contrast, a study of prescriptions issued to patients over 50 years of age in Family 
Medicine clinics in Mexico City revealed that 80% of scripts had one or more DDIs and 3.8% 
had level 1 (contraindicated) drug interactions
7
. However, these studies are difficult to
compare. They differ in methodology, which DDIs are included, and what denominator is 
used to calculate prevalence and incidence. The only South African study listed in PubMed 
deals with DDIs and HIV drugs in a medical-aid database
20
. Of 43482 prescriptions analysed,
18035 P-DDIs were found. This study however excluded all anti-tuberculous medications. 
No studies were found in PubMed or Medline dealing with the prevalence of DDIs in primary 
healthcare in South Africa (23 May 2011).  
Aim: 
To investigate potential drug-drug interactions in the prescriptions issued at primary 
healthcare clinics in the George subdistrict. 
Objectives: 
1. To determine the prevalence of potential DDIs in prescriptions issued at four PHC
clinics in the George subdistrict. 
2. To determine the most common drugs involved.
3. To grade the levels of drug-drug interactions according to the OpeRational
Classification of drug interactions (ORCA)
 12, 13
.
4. To establish any association between specific chronic diseases and prescriptions
containing P-DDIs. 
5. To determine the effect that specialist prescribers from George Hospital have on the
prevalence of DDIs in the scripts of patients followed up in PHC clinics. 
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Methodology 
Ethics approval was obtained from the University of Stellenbosch Ethics Committee, 
reference N09/08/203
†
. The main ethical consideration was protecting patient privacy. This
was dealt with by using a de-identified database and password protection of sensitive data. A 
waiver of informed consent was granted by the ethics committee. Permission for the study 
was obtained from the Western Cape Department of Health, reference 19/18/RP114/2009
‡
.
The study sites were four primary health care clinics in the George subdistrict of Western 
Cape: 
 Thembalethu
 Sentrum
 Pacaltsdorp
 Conville
Design: 
A cross-sectional study of the drugs prescribed to patients in PHC clinics was used to 
determine the prevalence of P-DDIs and to evaluate associations. The study population was 
the patients making use of PHC facilities at the above clinics from 1
st
 February to 30
th
 April
2010. No other inclusion or exclusion criteria were applied. Simple random sampling was 
used. The number of patients who attended the clinics from 1 February to 30 April 2010 was 
obtained. Random numbers were generated by computer equivalent to the sample size 
(n=400) within these totals. These random numbers were used to draw the corresponding 
files. The sample size needed to estimate a proportion with a 95% Confidence Interval (CI) 
and a precision of 5% (Cp = 5%) was determined to be at least 385 scripts. Four hundred 
scripts were analysed. 
†
 See Appendix 1 
‡
 See Appendix 2 
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Method of Data Collection: 
Data was collected from the prescriptions from patients’ files and recorded in a password 
protected database.  The variables included age, sex, all drugs prescribed concurrently during 
the period in question and chronic diseases recorded in the files. The data was transferred into 
a de-identified spread-sheet to protect the privacy of patients and prescribers. The drug lists 
were analysed using Medscape’s drug interaction checker for drug interactions 
(www.medscape.com) and verified using ePocrates® software as a form of concurrent 
convergent validity. These are valid and reliable instruments to detect DDIs.
26, 32 
ePocrates®
compares favourably with drug compendia for accuracy
27
. The evidence for an interaction
was obtained from Medscape and recorded in a separate file linked to the spreadsheet. Each 
interaction was classified according to the ORCA classification
12, 13
. Data from each site was
collected individually allowing analysis of this data separately and as part of the total. Rigour 
was ensured by linking a range of validity and reliability checks in the database and 
spreadsheet.
 
In order to distinguish trivial from significant effects the ORCA, classification 
levels 1 to 3 were identified (Table 1) and recorded as contraindicated, severe, or moderate 
interactions. 
Table 1 Hansten and Horn’s OpeRational Classification of drug interactions (ORCA). Adapted from references
 
10,12,16,39 
Level Management Examples 
1 
(Contraindicated) 
Avoid combination because the risk always outweighs the benefit nitroglycerin - sildenafil 
2 
 (Severe) 
Usually avoid the combination 
   -alternatives are available for one or both drugs 
  -avoid unless the benefit outweighs the risk of the DDI 
simvastatin and amiodarone 
3 
(Moderate) 
Minimise risk 
   -consider alternatives that may be less likely to cause DDI 
   -circumvent the interaction by taking precautionary measures 
  -monitor for early detection of the DDI 
warfarin and rifampicin 
4 No special precautions needed as risk of adverse effect is small efavirenz and TMX/SMX 
5 Ignore as DDI does not occur per existing evidence paracetamol and codeine 
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Statistical Analysis 
The data was analysed by the researcher with support from the Centre for Statistical 
Consultation (CSC), Stellenbosch University, using STATISTICA version 10.0 
www.statsoft.com. Summary statistics were conducted using frequency tables, histograms, 
means and standard deviations.  Comparisons of different sub groups were done using the 
Chi-square test for comparing nominal responses and one-way ANOVA for comparing 
continuous responses. Analysis was done to determine associations between chronic disease 
conditions and DDIs. Similarly, the relationship between patients’ age and DDIs and between 
the numbers of drugs prescribed and DDIs were determined. The effect of prescribers from 
the George hospital specialist departments was also examined. A significance level of 5% 
was used for all hypotheses tested. 
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Results 
The following tables and figures that present the results deal firstly with the prevalence of P-
DDIs. Thereafter, the drugs that were involved are outlined and the findings as regards severe 
interactions as well as contra-indicated combinations are presented. Finally, the different 
associations that were investigated are detailed. 
There were 2265 drugs prescribed in the 400 scripts analysed, (5.66 drugs per script). Using 
Medscape’s interaction checker, 173 scripts (43.25%) were found to have at least one 
potential-drug-to-drug interaction. (Table 2) 
Table 2 Number of prescriptions containing P-DDIs at the four PHC clinics. The percentage of the scripts containing a DDI 
is in brackets. 
Site Scripts 
analysed 
Moderate 
Interactions 
Severe 
Interactions 
Contraindicated 
Combinations 
Thembalethu 200 81 (40.5%) 5 (2.5%) 1 (0.5%) 
Conville 65 24 (36.9%) 3 (4.6%) 0 (0.0%) 
Sentrum 65 35 (53.9%) 9 (13.9%) 1 (1.5%) 
Pacaltsdorp 70 28 (40.0%) 4 (5.7%) 0 (0.0%) 
Totals 400 168 (42.0%) 21 (5.3%) 2 (0.5%) 
Statistica Chi-square(df=3)=4.68, 
p=.99660 
Chi-square(df=3)=10.63, 
p=.01392 
Chi-square(df=3)=2.26, 
p=.52055 
Overall 366 potential-drug-interactions were present, an average of 0.92 potential-
interactions per script. (Table 3) 
Table 3 Breakdown of the total P-DDIs found 
Total potential drug interactions 366 
No. of moderate interactions 336 
No. of severe interactions 28 
No. of contraindicated interactions 2 
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Table 4 presents the fifteen drugs that were most commonly prescribed in descending order of 
frequency.  
Table 4 Top fifteen drugs prescribed 
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1 Paracetamol  162 
2 Aspirin 131 
3 Enalapril 124 
4 Hydrochlorothiazide 109 
5 Amlodipine 99 
6 Simvastatin 86 
7 Ung methyl salicylate 77 
8 Ibuprofen 71 
9 Amoxicillin 63 
10 Metformin 57 
11 Atenolol 49 
12 Amitriptyline 48 
13 Vit Bco 45 
14 Furosemide 40 
15 Chlorpheniramine 37 
Figure 1 Top ten causes of P-DDIs and the number of times they were prescribed 
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Figure 1 presents the drugs that were most commonly involved in potential-drug-interactions. 
Some drugs were involved in more DDIs than the number of times that they were prescribed. 
For example, digoxin ranked 14 as a cause of P-DDIs. It was prescribed only four times but 
was involved in ten P-DDIs. Furosemide, spironolactone, simvastatin and metoclopramide 
were the drugs implicated in moderate interactions with digoxin. Because these drugs are 
often prescribed together, it is easy to understand how digoxin had a 250% risk of being 
involved in a P-DDI if it was prescribed. The most common interaction occurred between 
enalapril and aspirin (Level 3), with 86 occurrences.  
Table 5 represents the drugs that were involved in P-DDIs more often than they were 
prescribed. Many of these were introduced by specialist departments from the local regional 
hospital. The final column represents the number of DDIs divided by the number of times the 
drug was prescribed expressed as a percentage to indicate risk. 
Table 5 Drugs at highest risk of being involved in an interaction if prescribed. 
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1 Digoxin 4 10 250.0% 
2 Amphotericin B loz 1 2 200.0% 
3 Lamotrigine 1 2 200.0% 
4 Venlafaxine 1 2 200.0% 
5 Warfarin 12 21 175.0% 
6 Propranolol 2 3 150.0% 
7 Telmisarten 2 3 150.0% 
8 Fluoxetine 19 27 142.1% 
9 Losartan 3 4 133.3% 
10 Enalapril 124 161 129.8% 
Table 6 contains the top twenty prescribed drugs that were not involved in a P-DDI, (except 
amlodipine which was prescribed 99 times but was only implicated in a single P-DDI with 
Titralac® (calcium carbonate).  
Table 6 Drugs least likely to cause DDIs 
Amlodipine Cefixime Hydralazine 
Ung methyl salicylate Doxazosin Cardura XL Stavudine 
Amoxicillin Efavirenz Normal saline nose drops 
Vit Bco Medroxyprogesterone acetate Promethazine 
Chlorpheniramine Omeprazole Ipratropium bromide 
Codeine Vidaylin / multivitamins Orphenadrine 
Lamivudine Sorol citrate powder 
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Severe Interactions 
Twenty-one prescriptions contained a total of 28 level 2 (severe) P-DDIs. These were due to 
15 different interactions. (Table 7) 
Table 7 Severe interactions 
Severe Drug Interactions Occurrences 
Warfarin ↔  Aspirin 6(21.43%) 
Fluoxetine ↔  Clonazepam 3(10.71%) 
Tramadol ↔  Amitriptyline 3(10.71%) 
Warfarin ↔  Allopurinol 3(10.71%) 
Ferrous sulphate ↔  Doxycycline 2(7.14%) 
Tramadol ↔  Fluoxetine 2(7.14%) 
Allopurinol ↔  Theophyllin 1(3.57%) 
Amphotericin B ↔  Anusol 1(3.57%) 
Amphotericin B ↔  Budesonide 1(3.57%) 
Ferrous sulphate ↔  Ciprofloxacin 1(3.57%) 
Lamotrigine ↔  Valproic Acid 1(3.57%) 
Methotrexate ↔  Diclofenac 1(3.57%) 
Quinine ↔  Rifampicin 1(3.57%) 
Spironolactone ↔  Potassium  chloride 1(3.57%) 
Warfarin ↔  Metronidazole 1(3.57%) 
Warfarin was involved in ten and aspirin in six severe P-DDIs. (Figure 2) 
Figure 2 Drugs Involved in Severe Interactions 
Contraindicated Combinations 
Two instances of contraindicated combinations were found. Hyoscine butyl bromide and oral 
potassium chloride were prescribed together at Thembalethu while simvastatin with 
verapamil were prescribed at Sentrum clinic. 
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The Associations Investigated 
1. Diseases associated with DDIs
The top four diagnoses recorded in the files were hypertension, type-2-diabetes, Human 
Immunodeficiency Virus infection (HIV) and osteoarthritis. These were examined to 
determine the percentage of scripts with a P-DDI. The percentage of scripts containing a 
severe P-DDI was also determined. (Table 8)  
Table 8 Chronic diseases and P-DDIs (Total number of scripts = 400) 
Disease Number of 
patients 
diagnosed 
with 
Percentage of 
scripts 
containing a 
potential DDI 
Percentage of 
scripts with a 
potentially 
severe DDI 
Average 
number of 
drugs per 
script 
Hypertension 150 (37.5%) 72.7% 6.7% 7.2 
Type 2 Diabetes 58 (14.5%) 81.0% 12.1% 8.3 
HIV 39 (9.8%) 38.5% 2.6% 7.7 
Osteoarthritis 32 (8.0%) 81.3% 6.3% 8.9 
2. The effect of prescribers from George hospital
A total of 109 (27%) of the prescriptions had evidence of input from the George provincial 
regional hospital (GH) specialist 
departments. Of the 173 
prescriptions that contained at 
least one DDI, 41% had input 
from GH.  
Significantly more level 2 
interactions were found in the 
group of scripts that were 
influenced by GH. Most (81%;
17/21) of the severe interactions 
came from this group of patients compared to 19% (4/21) that only had input from the PHC 
staff.  
In the group where the drugs originated from George hospital, 63.3% (69/109) of the scripts 
had at least one moderate interaction with a corresponding figure of 34% (99/291) for the 
group where all the drugs originated from the PHC clinics only. (Chi-square (df=1) =27.77, 
p<0.001). 
0
20
40
60
80
100
George input
PHC Only
Figure 3 P-DDIs with input from George hospital compared to P-DDIs with 
input from PHC staff only (Chi-squared(df=2)=16.18, p=0.00031) 
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 For contraindicated combinations, each group had one; GH = 1/109 = 0.9% and PHC = 
1/191=0.5%. 
3. Age
The mean patient age of the sample was 41 years (95% CI, 39.3-43.3). The mean age for 
moderate interactions was 52.6 years (95% CI, 49.8-55.3), for severe interactions, 52.5 years 
(95% CI, 43.8-61.2), and contraindicated combinations, 67 years (95% CI, 38.7-95.3). The 
mean ages do not differ significantly as tested with ANOVA where F (2,170) = 0.869 with 
p=0.42 >0.05.  
4. Gender
Although 65.5% of the patients in the sample were female, gender was not associated with an 
increased risk for P-DDIs; 43.13% of female and 43.48% of male scripts contained at least 
one P-DDI. 
5. Effect of poly-pharmacy on the number of DDIs
Using the number of occurrences one can determine the average number of DDIs per script. 
By plotting this against the number of concurrent drugs prescribed, the tendency is for the 
number of DDIs to increase as the number of drugs used concurrently increases. (Figures 4 
and 5).  
Figure 4: The effect of poly-pharmacy on the prevalence of DDIs: The red and blue line represents the average P-DDIs per 
script. The relationship is greater than linear as shown by the blue line. 
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Figure 5 The dark blue area represents the percentage of patients who have at least one P-DDI for the number of drugs 
prescribed and the light blue is the percentage with more than one P-DDI.  
Discussion 
Drug-to-drug-interactions occur when the precipitant drug alters the effect of the object 
drug
8
. Over 9000 DDIs are recognised
41
. Most are trivial with only a few being clinically
significant
9
. The outcome may be harmful, even fatal, if the interaction increases toxicity or
reduces the intended effect of the object drug. Other effects include gastrointestinal bleeding, 
renal dysfunction, electrolyte imbalances, hypertension/hypotension, and arrhythmias
10
.
Many interactions are acceptable, for example enalapril and low dose aspirin, a moderate 
(level three) interaction, responsible for 86 interactions in this study. Aspirin antagonises the 
antihypertensive effect of ACE-inhibitors, increasing mean blood-pressure. There may be 
other negative effects
35-37
.
The prevalence of DDIs in the George subdistrict is half of that found in family medicine 
clinics in Mexico City, where 80.0% of the scripts of elderly patients contained P-DDIs
8
.
However the studies are not directly comparable as they only looked at patients older than 50 
years. The prevalence of severe interactions compares with a recent Spanish study which 
found the prevalence of potentially severe interactions to be 5.8% in family medicine clinics 
in Murcia
32
. The most common drugs involved were omeprazole, diazepam, warfarin,
ibuprofen and calcium. In the present study warfarin and NSAIDs (aspirin, ibuprofen and 
diclofenac) featured prominently as did benzodiazepines. Omeprazole was found to be one of 
the safer drugs in this study, being prescribed thirteen times with no interactions (Table 5). 
The use of different interaction checkers complicates comparisons. 
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The increasing risk of P-DDIs with age and poly-pharmacy is well documented.
7, 9, 15, 22, 23, 30
However, the relatively low risk of P-DDIs in patients diagnosed with HIV was unexpected 
(Table 7). At 7.7 drugs per script, the average drugs-per-script was higher than the 5.7 drugs-
per-script of the sample. Yet only 38.5% of scripts had moderate interactions and 2.6% of the 
scripts included a potentially severe-interaction. Snyder found that 77% of scripts of 
hospitalised HIV patients in tertiary care in Florida
 
had medical errors of which 12% were 
due to DDIs
34
. Our study involved only ambulatory clinic patients; therefore the studies are
not directly comparable. Furthermore, most were on regimen 1 of the SA national HIV 
guidelines, which excludes protease-inhibitors. In medical-aid patients in South Africa, 
Katende-Kyenda found 960 P-DDIs in 47085 prescriptions (2%) in private practice
20
.
However, large numbers of patients were on only one or two drugs, which may explain the 
low prevalence of DDIs in this study. 
The scripts from files where type 2 diabetes was diagnosed recorded the highest prevalence 
of potentially severe interactions (12.1%). This risk may be amplified by altered 
pharmacokinetics as a result of disease factors such as impaired renal function. It is probable 
that P-DDIs are more likely to manifest as clinical effects in these patients. 
DDIs are predictable and preventable. While we need to take note of the effects of moderate 
interactions, these seldom cause life-threatening complications. Severe (level-two) 
interactions however require action to prevent harm. Level-one interactions should never be 
prescribed. It would seem prudent to provide some form of intervention to decrease the 
prevalence of level one and level two interactions. While sophisticated technological 
advances have reduced the risk in first world countries significantly, 
12, 26, 27
 it is unlikely that
the South African public health service will embrace these technologies in the immediate 
future. Furthermore, electronic alerts are inconsistent, vary between products and are often 
ignored by prescribers and pharmacists. 
26, 27, 31, 40
However, simple interventions such as drug reviews and quality improvement cycles 
focusing on reducing P-DDIs are effective and practical solutions
22
. Improved
communication between specialist departments and PHC clinics are also likely to have a 
positive effect
21
.
Regular medication reviews have been shown to substantially reduce the risk of DDIs and 
rationalise prescribing in patients with poly-pharmacy,
 
reducing the number of medications 
prescribed by 20%
22
. Dosages modified and medications prescribed by other healthcare
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providers may be discovered that the family physician was unaware of. Identifying over the 
counter (OTC) medications is also possible by asking the patient what other medicines (s)he 
uses. Regular medication reviews would create awareness amongst prescribers and patients 
concerning the risks of poly-pharmacy, including DDIs.  
This study may help to target interventions aimed specifically at clinically important 
interactions by identifying the severe as well as common interactions found in typical PHC 
settings in South Africa. This study identified the following risk factors: 
1. Drugs that are involved in P-DDIs more often than they are prescribed: Digoxin,
amphotericin B, lamotrigine, venlafaxine, warfarin, propranolol and telmisarten
(Table 5)
2. Drugs that commonly cause P-DDIs: Enalapril, aspirin, ibuprofen, furosemide,
fluoxetine, amitriptyline and warfarin (Figure 1)
3. Drugs that cause potentially severe interactions: Warfarin, aspirin, fluoxetine,
tramadol, allopurinol, amitriptyline and clonazepam (Figure 2)
4. Poly-pharmacy (more than five drugs per prescription)
5. Patients older than fifty years
6. Chronic diseases: Type 2 diabetes, hypertension or osteoarthritis
7. Involvement of specialist departments from the regional hospital.
Identifying these patients and exposing them to regular medication reviews by a family 
physician is likely to be beneficial and cost-effective. However, relying on memory, drug 
compendia or software alone is unlikely to be effective
32
.
Limitations of this study 
This study only detected potential interactions. Only a few people experience the effects of 
interactions.  Therefore the clinical effects are considerably less than the figures presented 
here.  
This study was also completely reliant on the data as recorded in the patients’ files. No 
attempt was made to interpret or correct possible diagnostic inaccuracies.  
Drug-interaction checkers vary in their sensitivity and specificity
41
. Where Medscape and
ePocrates
®
 had different results the results from Medscape were recorded. New drug-
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interactions are continually being discovered. The results were 
correct as per Medscape’s interaction checker on 31 January 2011. 
The sample size in this study is small, making the identification of 
associations for contraindicated combinations (level 1 
interactions) statistically insignificant. Only four PHC sites were 
evaluated, although these probably reflect the broader population 
at risk in PHC clinics in the Western Cape. 
This was a cross-sectional study, thus seasonal variations, 
changing prescribers or changing illness profiles were not taken 
into account. 
Conclusion/recommendations 
As in PHC clinics in other developing countries, P-DDIs are 
common yet unrecognised by prescribers in PHC clinics in the 
George subdistrict of South Africa. Although the prevalence of 
clinically significant events is presumed to be much lower than the 
figures for P-DDIs found in this study, they are still likely to be 
significant. By recognising this and implementing simple cost-
effective mechanisms aimed at reducing DDIs, medical 
practitioners are likely to reduce the risk of DDIs to the patients. 
Electronic media are expensive and drug compendia clumsy. 
Identification of high risk patients and evaluating their scripts as 
part of a regular medicine review, as well as improving 
communication between prescribing physicians, is likely to 
improve clinical governance and result in a decrease the number 
of P-DDIs prescribed. The risk factors identified in this study 
include poly-pharmacy, elderly patients, multiple prescribers, 
prescription of specific drugs and type 2 diabetes, hypertension 
and osteoarthritis. Scheduling these patients to have a medicine 
review performed by a family physician and then annual follow-
up reviews may be prove beneficial to the patients whilst reducing 
the cost of drugs. 
The most important findings of this 
study are: 
1. Poly-pharmacy is rife, with
patients receiving up to twenty
drugs per script.
2. Potential drug-drug interactions
are common; 40.2% of scripts
contained at least one P-DDI.
3. More than 5% of prescriptions
contained a potentially severe-
interaction and 1 in 200 scripts
have a level-one drug
interaction.
4. Multiple prescribers, viz.
specialist departments from a
regional hospital, increased the
risk of a script containing a P-
DDI from PHC clinics.
5. Common diseases such as
hypertension and diabetes are
the diagnoses most likely to be
associated with P-DDIs. Poly-
pharmacy is common in HIV
patients but there are fewer
interactions compared to
diabetes, hypertension and
osteoarthritis.
6. Warfarin and aspirin are the
most common cause of severe P-
DDIs.
7. The elderly are more likely to be
prescribed P-DDIs
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